Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001783325 | SCV002023801 | pathogenic | not provided | 2022-03-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002034563 | SCV002172832 | pathogenic | Glycogen storage disease, type II | 2023-04-03 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1322950). This premature translational stop signal has been observed in individual(s) with Pompe disease (PMID: 10737124). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Leu811Profs*73) in the GAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). |
Baylor Genetics | RCV002034563 | SCV005058760 | pathogenic | Glycogen storage disease, type II | 2023-12-24 | criteria provided, single submitter | clinical testing |